A lack of clear information on COVID risk is stopping people with long-term conditions accessing the care they need – and could be storing up problems for the future.
It has never been more important to ensure people have access to trusted health information – and the whole health sector must work together to make it possible.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.